Andros Pharmaceuticals Co (ROCO:6917) Operating Margin %: -643.69% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6917 Andros Pharmaceuticals Co Ltd ROCO:6917
41 GF Score
Price NT$34.50
GF Value NT$165.02
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Andros Pharmaceuticals Co Operating Margin %?

Andros Pharmaceuticals Co ROCO:6917 -3.09% 41 Operating Margin % is -643.69% as of Dec. 2025. GuruFocus rates ROCO:6917 with a GF Score™ of 41/100 and a GF Value™ of NT$165.02 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 939 Biotechnology companies, Andros Pharmaceuticals Co ranks worse than 81.26% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Andros Pharmaceuticals Co's Operating Income for the six months ended in Dec. 2025 was NT$-35.30 Mil. Andros Pharmaceuticals Co's Revenue for the six months ended in Dec. 2025 was NT$5.48 Mil. Therefore, Andros Pharmaceuticals Co's Operating Margin % for the quarter that ended in Dec. 2025 was -643.69%.

Warning Sign:

Andros Pharmaceuticals Co Ltd operating margin has been in a 5-year decline. The average rate of decline per year is -61.8%.

The historical rank and industry rank for Andros Pharmaceuticals Co's Operating Margin % or its related term are showing as below:

ROCO:6917' s Operating Margin % Range Over the Past 10 Years
Min: -44142.86   Med: -2729.77   Max: -262.19
Current: -1363.3


ROCO:6917's Operating Margin % is ranked worse than
81.26% of 939 companies
in the Biotechnology industry
Industry Median: -86.33 vs ROCO:6917: -1363.30

Andros Pharmaceuticals Co's 5-Year Average Operating Margin % Growth Rate was -61.80% per year.

Andros Pharmaceuticals Co's Operating Income for the six months ended in Dec. 2025 was NT$-35.30 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-75.64 Mil.


Andros Pharmaceuticals Co  (ROCO:6917) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Andros Pharmaceuticals Co Operating Margin % Related Terms


Andros Pharmaceuticals Co Operating Margin % Historical Data

* Premium members only.

The historical data trend for Andros Pharmaceuticals Co's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Andros Pharmaceuticals Co Operating Margin % Chart

Andros Pharmaceuticals Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial -262.19 -2,729.77 -9,156.52 -44,142.86 -1,363.30

Andros Pharmaceuticals Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13,687.76 -51,550.00 -39,893.80 -63,025.00 -643.69

ROCO:6917 vs VRTX, REGN, ALNY: Operating Margin % Comparison

For the Biotechnology subindustry, Andros Pharmaceuticals Co's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Andros Pharmaceuticals Co Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Andros Pharmaceuticals Co's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Andros Pharmaceuticals Co's Operating Margin % falls into.


ROCO:6917
41GF Score
Andros Pharmaceuticals Co Ltd ROCO:6917
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Andros Pharmaceuticals Co Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Andros Pharmaceuticals Co's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=-75.636 / 5.548
=-1,363.30 %

Andros Pharmaceuticals Co's Operating Margin % for the quarter that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=-35.3 / 5.484
=-643.69 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of -643.69% mean?
Andros Pharmaceuticals Co (ROCO:6917) has a Operating Margin % of -643.69% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Andros Pharmaceuticals Co and its competitors. According to the industry distribution chart, Andros Pharmaceuticals Co ranks #763 out of 939 companies in the Biotechnology industry, placing it in the top 81.3%.
Is Andros Pharmaceuticals Co's Operating Margin % too high?
Andros Pharmaceuticals Co's current Operating Margin % is -643.69%. Based on the distribution chart, Andros Pharmaceuticals Co ranks #763 out of 939 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Andros Pharmaceuticals Co has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Andros Pharmaceuticals Co's Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Andros Pharmaceuticals Co ranks #763 out of 939 companies for Operating Margin %. This places Andros Pharmaceuticals Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Andros Pharmaceuticals Co and its competitors. Andros Pharmaceuticals Co's current Operating Margin % is -643.69%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Andros Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Andros Pharmaceuticals Co (ROCO:6917) is currently considered Possible Value Trap. The stock's GF Value™ is NT$165.02, compared to a current price of NT$34.50 — trading 79.1% below its estimated fair value. The current Operating Margin % is -643.69%. Andros Pharmaceuticals Co's overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Andros Pharmaceuticals Co (ROCO:6917), the current Operating Margin % is -643.69% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Andros Pharmaceuticals Co (ROCO:6917) Overvalued in 2026?

Based on GuruFocus' analysis, Andros Pharmaceuticals Co stock appears to be undervalued. The current stock price of NT$34.50 is trading 79.1% below its estimated GF Value™ of NT$165.02. GuruFocus considers Andros Pharmaceuticals Co to be Possible Value Trap.

Key valuation signals for ROCO:6917:

  • Operating Margin %: -643.69%
  • GF Value™: NT$165.02 vs. price of NT$34.50 (79.1% below fair value)
  • GF Score™: 41/100 with 4 warning signs

No single metric tells the full story. See the ROCO:6917 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Andros Pharmaceuticals Co Business Description

Address No. 22, Sec. 2, Shengyi Road, 6th Floor, Building D, Biotech Building, Hsinchu Biomedical Science Park, Hsinchu County, Zhubei City, TWN, 30261
Andros Pharmaceuticals Co Ltd is a biopharmaceutical company engaged in developing novel drug delivery platform technologies. The firm focuses on the development of topical new dosage forms and non-viral gene delivery systems, with the current pipeline indicated for pain management, DNA repair, and gene therapy. Its product line comprises New Dosage Forms (Topical), Super Generics (Topical), High-End Cosmetic Ingredients (Topical), and Gene Delivery Systems (Injectable).
41GF Score

Get the complete analysis for ROCO:6917

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$34.50
Price
NT$165.02
GF Value